Phase I first-in-human dose-escalation trial of ARI-HER2 (HER2BBz CAR-T cells) in HER2-positive advanced breast cancer
Sponsor: Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Phase: 1
Disease: HER2-positive advanced breast cancer
EU trial number: 2026-527365-30-00
Population: Adults with HER2-positive advanced breast cancer undergoing first-in-human dose escalation of ARI-HER2, a HER2-directed chimeric-antigen-receptor T-cell therapy.
Register Investigator Interest
Interested in offering this trial to suitable patients?